Anika Therapeutics | ANIK - Capital Ordinário





Capital Ordinário Alterar Data
Abbott USD 1.74B 2.94M 2026-03
Agenus USD 35.32M 2.51M 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 137.39M 1.69M 2025-12
Enanta Pharmaceuticals USD 212K 1000 2023-12
Halozyme Therapeutics USD 118.52M 741K 2026-03
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 216.52M 2.27M 2026-03
Integra LifeSciences USD 77.82M 69K 2026-03
Intrexon USD 0 0 2024-06
J&J USD 2.41B 1.35M 2026-03
Karyopharm Therapeutics USD 18.31M 18.3M 2025-12
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
MacroGenics USD 63.56M 241K 2026-03
Merit Medical Systems USD 59.65M 231K 2026-03
Rigel Pharmaceuticals USD 17K 158K 2024-06
Sanofi EUR 1.21B 8.25M 2026-03
Smith & Nephew USD 875.96M 1.61M 2025-12
Stryker USD 382.98M 584K 2026-03
Veracyte USD 79.79M 743K 2026-03
Xencor USD 74.06M 2.19M 2026-03
Zimmer Biomet Holdings USD 195.5M 2.68M 2026-03